Skip to main content
. Author manuscript; available in PMC: 2016 Mar 1.
Published in final edited form as: Blood Rev. 2014 Dec 17;29(2):137–142. doi: 10.1016/j.blre.2014.12.003

Figure 1.

Figure 1

Response to nilotinib and dasatinib compared to imatinib. Panel A and B demonstrate complete cytogenetic response (CCyR) and major molecular response (MMR) achieved at 12 months in ENESTnd [nilotinib (N) vs. imatinib (I)] and DASISION [dasatinib (D) vs. imatinib (I)] trials. Panel C shows progression to accelerated/blastic phase with nilotinib (N) and dasatinib (D) in comparison to imatinib (I), at the conclusion of the first 12 months of follow-up. Numbers at the top represent P values.